Do Peptides Need to Be Injected?
While subcutaneous injection is the most common and well-studied administration route for research peptides, it’s not the only option. Some peptides can be administered orally, nasally, or topically depending on the compound and research goals.
Injectable Peptides (Most Common)
The majority of research peptides are administered via subcutaneous injection for good reason: high bioavailability (65-95%), consistent absorption, and well-established pharmacokinetics. Peptides like semaglutide, BPC-157, ipamorelin, and TB-500 are typically researched via injection.
Oral Peptides
Some peptides can be taken orally: Oral BPC-157 — Available in tablet form for GI-focused research. While systemic bioavailability is low, local effects in the GI tract are the primary research interest. Oral semaglutide (Rybelsus) — Uses SNAC absorption enhancer technology, though this is a pharmaceutical product, not a research peptide.
Nasal Peptides
Semax and Selank are commonly researched via nasal administration. This route provides 10-30% bioavailability and offers direct access to the CNS via olfactory pathways, making it ideal for nootropic peptide research.
Topical Peptides
GHK-Cu is frequently studied in topical formulations for skin research. Copper peptides can penetrate the skin barrier and exert local effects on collagen synthesis and wound healing.
Which Route is Best?
The optimal route depends on the specific peptide, the target tissue, and research objectives. Injectable remains the gold standard for systemic delivery, but alternative routes are valuable for specific applications. See our bioavailability comparison for detailed route-by-route analysis.
Related Articles: SubQ vs IM Injection | Can Peptides Be Taken Orally? | Bioavailability Guide
For research use only. Browse all peptide formats at Proxiva Labs with verified COAs.